Skip to main content
. 2020 Jan 3;60(2):75–82. doi: 10.2176/nmc.oa.2019-0194

Fig. 4.

Fig. 4.

Series of MRI scans with contrast enhancement of a 41-year-old woman (case no. 5). After receiving bevacizumab, the volume of her left VS shrank to 61% from baseline volume in the 3rd month, then, it regrown to reach 223% in 18th month. A second trial of bevacizumab was restarted, and it shrank again to reach 144% in the 21st month and again relapsed to reach 438% in the 33rd month.